<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937857</url>
  </required_header>
  <id_info>
    <org_study_id>JXQF-XYP-1606</org_study_id>
    <nct_id>NCT02937857</nct_id>
  </id_info>
  <brief_title>An Add-on Study to Evaluate the Efficacy and Safety of Xiyanping Injection in Pediatric Bronchitis Patients.</brief_title>
  <official_title>A Multicenter, Randomized, Open Label, Add-on Study to Assess Efficacy and Safety of Xiyanping Injection in Subjects With Pediatric Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open Label,add-on study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an add-on study of efficacy and safety of intravenous injection of Xiyanping&#xD;
      injection in subjects with pediatric bronchitis.&#xD;
&#xD;
      The purpose to determine the efficacy and safety of conventional treatment combined with or&#xD;
      without Xiyanping injection in the treatment of pediatric bronchitis and to further evaluate&#xD;
      the clinical value of Xiyanping injection in shortening the course of pediatric bronchitis&#xD;
&#xD;
      The study will enroll 240 Pediatric bronchitis volunteers, who will be randomized into 2&#xD;
      groups (1:1 ratio): volunteers from the first group will receive Routine treatment for&#xD;
      pediatric bronchitis and Xiyanping injection; volunteers from the second group will receive&#xD;
      Routine treatment for pediatric bronchitis. Xiyanping injection will be administration as&#xD;
      intravenous injection of 0.2-0.4mL/kg/day once daily for 5 days concomitantly with Routine&#xD;
      treatment for pediatric bronchitis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to total score of the clinical symptoms/signs decreased more than 70% from baseline</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The total efficiency rate</measure>
    <time_frame>Day 3 and Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to defervescence</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day(s) of Hospital Stay</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs and Symptoms Score from baseline</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic consumption</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
    <description>check and record the usage of antibiotic,including durg Utilization Rate and the duration of usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of Inhaled corticosteroids</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
    <description>check and record the usage of Inhaled corticosteroids,including durg Utilization Rate and the duration of usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complication</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
    <description>record the incidence of new complication after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum status</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
    <description>record the incidence of expectoration and the day of expectoration disappear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expenditure of therapeutic drug</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total expenditure of treatment</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
    <description>Expenditure of treatment include the cost of durg, hospitalization,examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events</measure>
    <time_frame>up to 30 days after the last Administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Bronchitis</condition>
  <arm_group>
    <arm_group_label>Standard treatment only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment only such as antiasthmatic, expectorant and antipyretic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment+Xiyanping injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment only</intervention_name>
    <description>standard treatment， such as antiasthmatic,expectorant,antipyretic</description>
    <arm_group_label>Standard treatment only</arm_group_label>
    <other_name>antiasthmatic,expectorant,antipyretic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment+Xiyanping injection</intervention_name>
    <description>standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.</description>
    <arm_group_label>Standard treatment+Xiyanping injection</arm_group_label>
    <other_name>antiasthmatic,expectorant,antipyretic + Xiyanping injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of pediatric bronchitis with hospital treatment needed&#xD;
&#xD;
          -  Males and female subjects&#xD;
&#xD;
          -  Age between 1 and 3 years old&#xD;
&#xD;
          -  With fever, cough, gasp and expectoration symptoms&#xD;
&#xD;
          -  Have wheeze and/ or mid-fine rales on one's lungs&#xD;
&#xD;
          -  White blood cell count &lt; 12 x 109 / L, categorized priority to leukocyte&#xD;
&#xD;
          -  C-reactive protein≤8mg/L or normal Super C- reactive protein&#xD;
&#xD;
          -  Had experienced ≤48 h course before enrollment&#xD;
&#xD;
          -  Previous Wheezing episodes≤2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with severe clinical symptoms, meet any of the following：&#xD;
&#xD;
               -  SaO2≤0.92;（2）Shock or disturbance of consciousness;（3） Significantly speed up&#xD;
                  breathing , rapid pulse accompany with severe respiratory distress; or（4）Repeated&#xD;
                  occurrence of apnea or slow and irregular respiration;&#xD;
&#xD;
          -  Acute infectious disease such as measles, pertussis and influenza&#xD;
&#xD;
          -  Participants with bronchial asthma, bronchopneumonia and other respiratory diseases&#xD;
&#xD;
          -  Chronic lung diseases&#xD;
&#xD;
          -  Participants with complicated pyopneumothorax, airway obstruction, toxic&#xD;
             encephalopathy, cardiac failure or respiratory failure&#xD;
&#xD;
          -  Participants with complicated severe underlying myocardial, liver, kidney, digestive&#xD;
             and hematopoietic system diseases&#xD;
&#xD;
          -  Severe malnutrition and history of immune deficiency which may seriously affect the&#xD;
             self-limiting process of the course&#xD;
&#xD;
          -  Participants with epilepsy and other disturbances of central nervous system&#xD;
&#xD;
          -  Participants with congenital diseases and psychosis&#xD;
&#xD;
          -  use of any other antiviral drugs within the 2 weeks before enrollment&#xD;
&#xD;
          -  use of systemic hormone within the 2 weeks before enrollment&#xD;
&#xD;
          -  Participants had a history of allergic constitution and drug allergy; Allergenic to&#xD;
             XiYanPing injection and Andrographolide&#xD;
&#xD;
          -  Participants participated in other clinical research in the last three months&#xD;
&#xD;
          -  Any condition which would make the subject, in the opinion of the investigator or&#xD;
             designee, not suitable for the study for any reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu Han Min, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Xiao</last_name>
    <phone>010-84682600</phone>
    <email>chenxiao@sh-qingfeng.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou women and children health care center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510623</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deng Li, professor</last_name>
      <phone>020-38076348</phone>
      <email>drdengli@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipyretics</mesh_term>
    <mesh_term>Expectorants</mesh_term>
    <mesh_term>Anti-Asthmatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

